CellaVision AB: Interim report January - June 2012
(Thomson Reuters ONE) -
Strong sales and doubled profit for the first half of 2012
January 1 - June 30, 2012
* Net sales increased by 16 % to SEK 83.8 million (72.5)
* The operating profit increased to SEK 9.9 million (7.1)
* Profit before tax increased to SEK 9.4 million (4.8)
* Earnings per share were SEK 0.24 (0.10)
* Cash and cash equivalents increased to SEK 47.5 million (42.7) at the end of
the period
* Launch of CellaVision® DM96 Vet for veterinary medicine in North America
April 1 - June 30, 2012
* Net sales increased by 4 % to SEK 43.4 million (41.9)
* The operating result was SEK 4.5 million (4.7)
* Profit before tax was SEK 5.0 million (4.5)
* Earnings per share were SEK 0.13 (0.09)
* Launch of CellaVision® Image Capture System for small laboratories in
networks
* Management team reinforced with VP Sales & Business Development
* New head of subsidiaries in North America appointed
Key ratios
(SEK million) April-June April-June Jan-June Jan-June Full year
2012 2011 2012 2011 2011
Net sales 43.4 41.9 83.8 72.5 155.4
Gross profit 28.7 25.7 55.8 46.5 101.4
Operating profit/loss 4.5 4.7 9.9 7.1 17.8
Operating margin, % 10.5 11.1 11.8 9.8 11.5
Profit/loss before tax 5.0 4.5 9.4 4.8 18.5
Total cash flow -9.0 2.5 -9.3 6.9 21.0
Comments by CellaVision's CEO Yvonne Mårtensson:
"All in all sales growth for the first six months of the year is in line with
our expectations. For the third quarter in a row we have sales of more than SEK
40 million and in the six-month period CellaVision has grown 16 % and almost
doubled its profit before tax.
During the period we continued to build the company and prepare for continued
geographical expansion and growth. At the moment the focus is on increasing our
visibility in the market through new products and support to our partners and
marketing offices. This year we have strengthened the organization on several
levels, from the management team and marketing offices to specialist services in
marketing and support.
On the product front this year we have launched two new products that strengthen
our position in hematology; a veterinary analyzer and a supplementary product
for hospitals in networks. We expect the first sales to be made before the end
of the year. At the AACC Annual Meeting in Los Angeles we will also give a
preview of a new web-based training tool adapted to customers with many users.
All three products were positively received when presented to prospective
customers.
During the quarter we employed two people located in Shanghai to provide support
and help our distributors' sales in China. There is a delay in reregistration of
the DM96 that may affect our deliveries in the latter part of 2012. However, the
delay is expected to have a marginal impact on CellaVision's total sales for
2012 and has no effect on long term."
For more information, please contact:
Yvonne Mårtensson, CEO Mobil: +46 708 33 77 82, email:
yvonne.martensson(at)cellavision.se
Johan Wennerholm, CFO Mobil: +46 708 33 81 68, email:
johan.wennerholm(at)cellavision.se
CellaVision AB: Interim report January - June 2012:
http://hugin.info/132164/R/1627418/520871.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1627418]
Unternehmensinformation / Kurzprofil:
Datum: 18.07.2012 - 08:30 Uhr
Sprache: Deutsch
News-ID 166265
Anzahl Zeichen: 4493
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 154 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision AB: Interim report January - June 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
